In a new sequencing study, researchers discovered a transcriptional signature in B cells associated with protection from SIV or HIV infection.
Research published this week suggests a specific fungus is present in Clostridium difficile infections, potentially presenting a future therapeutic target.
Take a look at this month’s industry headlines including US FDA approvals for two drugs – Xenleta™ and Pretomanid – in addition to an EMA decision for Zerbaxa®, partnerships for vaccine development and results on Ebola therapeutics.
Researchers recently profiled the single-cell transcriptomes of thousands of individual parasites to provide the first high-resolution atlas of malaria parasite gene expression across the lifecycle.
New research has discovered a link between dietary zinc intake and protection against Streptococcus pneumoniae, suggesting it aids the immune system.
Xenleta™ (lefamulin), developed by Nabriva Therapeutics, has been approved by the US FDA for adults with community-acquired bacterial pneumonia, marking the first new antibiotic with a novel mechanism of action to be approved in nearly two decades.
The US FDA has approved Pretomanid tablets in combination with bedaquiline and linezolid for the treatment of specific types of drug-resistant pulmonary tuberculosis.
A study of four Ebola therapeutics demonstrated that two drugs showed significantly improved survival rates, leading to the trial being halted early.
The first chlamydia vaccine to reach Phase I clinical trials has been observed to be safe and immunogenic in 35 women.